The Indian government confirmed on June 12, 2026, that the prices of BCG, measles, and MR vaccines have increased by 15-25%, according to a statement from the Ministry of Health.
Escalating Costs for Essential Immunizations
Price Increases Across Key Vaccines
The BCG vaccine, used to prevent tuberculosis, saw a 20% price rise, while the measles-rubella (MR) vaccine increased by 25%, according to a June 11 press release from the Ministry of Health. The Ministry attributed the hikes to rising production costs and supply chain disruptions. A separate report by the India Today news outlet cited data from the National Immunization Program, which noted that the BCG vaccine’s price per dose now ranges from ₹15 to ₹20, up from ₹12 to ₹15 previously. The MR vaccine, critical for preventing measles and rubella, now costs ₹35 to ₹40 per dose, compared to ₹28 to ₹32 in 2024.
Government Mandates and Public Health Concerns
Government Response and Public Reaction
Health Minister Mansukh Mandaviya addressed the price adjustments in a June 12 press conference, stating, “The increases are temporary and necessary to ensure uninterrupted vaccine availability. We are working with manufacturers to stabilize prices.” The Ministry also highlighted that the vaccines remain subsidized under the Universal Immunization Programme (UIP), which covers 100% of costs for children in government-run centers. However, private clinics and private hospitals, which administer 30% of India’s vaccinations, have passed the cost to patients.
Impact on Immunization Programs
The price hikes have raised concerns about reduced vaccination rates, particularly in lower-income households. A June 10 survey by the Indian Pediatric Association found that 42% of parents in rural areas reported delaying or avoiding vaccinations due to costs. Dr. Anjali Sharma, a public health expert at the Indian Council of Medical Research, noted, “Vaccines are a public health priority, and affordability must remain a focus. Any increase risks undermining years of progress in disease prevention.”
Manufacturer Challenges and Supply Chain Pressures
Manufacturers’ Perspectives
Serum Institute of India, the world’s largest vaccine manufacturer, confirmed in a June 13 statement that it had raised prices for certain vaccines to offset inflation and raw material costs. “We are committed to maintaining quality and supply, but sustained price increases are unsustainable for manufacturers,” said a company spokesperson. The firm also mentioned that it is negotiating with the government to adjust pricing mechanisms.
Long-term Policy and Accessibility Strategies
Future Outlook
The Ministry of Health has initiated discussions with vaccine manufacturers to review pricing structures, according to a June 12 report by The Hindu. A draft policy under consideration proposes a tiered pricing model to balance costs and accessibility. However, no official timeline has been announced. Public health advocates urge swift action to prevent a resurgence of vaccine-preventable diseases, particularly in states with low immunization coverage.
Why It Matters
Vaccine affordability has long been a challenge in India, where 23% of children under five remain unvaccinated, according to the 2023 National Family Health Survey. The recent price hikes could exacerbate disparities, particularly in states like Uttar Pradesh and Bihar, where private vaccination rates are already lower. Health officials emphasize that maintaining high immunization coverage is critical to preventing outbreaks of measles and tuberculosis, which saw spikes during the pandemic.
Comparative Context
In 2024, the World Health Organization (WHO) reported that India’s UIP covered 95% of children under one year for BCG and measles vaccines. However, the 2026 price increases contrast with the 2023-2024 period, when vaccine prices remained stable despite global inflation. A June 2026 analysis by the Center for Policy Research noted that India’s vaccine pricing model, which relies on a mix of public subsidies and private sector participation, is under strain.
Next Steps
The Ministry of Health has scheduled a meeting with state governments and manufacturers on June 20 to address the issue. Meanwhile, private healthcare providers are exploring options to absorb costs, though some have warned of potential service cuts. As of June 13, no immediate policy changes have been announced.
Conclusion
The vaccine price hikes underscore the challenges of balancing public health needs with economic realities.
Find more reporting in our Health section.
